HK1173973A1 - Antibody therapeutics with local activity in the digestive tract - Google Patents

Antibody therapeutics with local activity in the digestive tract

Info

Publication number
HK1173973A1
HK1173973A1 HK13101231.2A HK13101231A HK1173973A1 HK 1173973 A1 HK1173973 A1 HK 1173973A1 HK 13101231 A HK13101231 A HK 13101231A HK 1173973 A1 HK1173973 A1 HK 1173973A1
Authority
HK
Hong Kong
Prior art keywords
digestive tract
antibody therapeutics
local activity
activity
local
Prior art date
Application number
HK13101231.2A
Other languages
English (en)
Chinese (zh)
Inventor
Barbara S Fox
Douglas C Stafford
Original Assignee
Avaxia Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avaxia Biologics Inc filed Critical Avaxia Biologics Inc
Publication of HK1173973A1 publication Critical patent/HK1173973A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK13101231.2A 2009-10-15 2013-01-29 Antibody therapeutics with local activity in the digestive tract HK1173973A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25199609P 2009-10-15 2009-10-15
PCT/US2010/052934 WO2011047328A1 (en) 2009-10-15 2010-10-15 Antibody therapeutics with local activity in the digestive tract

Publications (1)

Publication Number Publication Date
HK1173973A1 true HK1173973A1 (en) 2013-05-31

Family

ID=43876600

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13101231.2A HK1173973A1 (en) 2009-10-15 2013-01-29 Antibody therapeutics with local activity in the digestive tract

Country Status (14)

Country Link
US (3) US20120258118A1 (xx)
EP (2) EP2488202B1 (xx)
JP (1) JP2013508300A (xx)
KR (1) KR20120098664A (xx)
CN (1) CN102596248A (xx)
AU (1) AU2010306563B2 (xx)
CA (1) CA2777823A1 (xx)
ES (1) ES2547872T3 (xx)
HK (1) HK1173973A1 (xx)
HU (1) HUE027077T2 (xx)
NZ (1) NZ599315A (xx)
PL (1) PL2488202T3 (xx)
PT (1) PT2488202E (xx)
WO (1) WO2011047328A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734139C (en) 2007-10-02 2019-12-24 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
CA2816551A1 (en) * 2010-11-03 2012-05-10 Mcmaster University Method of treating mucosal inflammation
CN103917555A (zh) * 2011-08-01 2014-07-09 艾瓦夏生物制剂公司 人tnf特异性的牛科动物多克隆抗体
US9580501B2 (en) * 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3553155A1 (en) 2018-03-12 2019-10-16 INDIAN OIL CORPORATION Ltd. Nano perovskite materials as combustion improver for liquid and gaseous fuels
GB201812261D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating oral mucositis
CN110672860B (zh) * 2019-11-04 2023-07-14 中国科学院近代物理研究所 五种细胞因子组合作为电离辐射损伤生物标志物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330338A (en) 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
CA2132953C (en) * 1992-03-26 2001-01-30 Howard C. Krivan Monospecific polyclonal antibodies to shiga-like toxins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
DE602004002275T2 (de) 2003-01-07 2007-09-06 Symphogen A/S Verfahren zur herstellung rekombinanterpolyklonaler proteine
US20040185047A1 (en) * 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
CN101715456A (zh) * 2007-04-16 2010-05-26 菲仕兰产品有限公司 来自乳汁的抗原特异性抗体、其制备方法以及应用
EP1982999A1 (en) * 2007-04-16 2008-10-22 Friesland Brands B.V. Milk derived antigen specific antibodies, methods of preparation and uses thereof
EP2215474A4 (en) * 2007-07-16 2012-07-18 Avaxia Biologics Inc ANTIBODY THERAPY FOR MODULATING THE FUNCTION OF DARM RECEPTORS
CA2734139C (en) * 2007-10-02 2019-12-24 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Also Published As

Publication number Publication date
AU2010306563B2 (en) 2013-11-28
PT2488202E (pt) 2015-10-19
PL2488202T3 (pl) 2015-12-31
NZ599315A (en) 2014-05-30
US20170008957A1 (en) 2017-01-12
CA2777823A1 (en) 2011-04-21
EP2488202A1 (en) 2012-08-22
KR20120098664A (ko) 2012-09-05
AU2010306563A1 (en) 2012-05-03
WO2011047328A1 (en) 2011-04-21
US20120258118A1 (en) 2012-10-11
HUE027077T2 (en) 2016-08-29
CN102596248A (zh) 2012-07-18
ES2547872T3 (es) 2015-10-09
EP2992900A1 (en) 2016-03-09
JP2013508300A (ja) 2013-03-07
US20140010822A1 (en) 2014-01-09
EP2488202A4 (en) 2013-01-23
EP2488202B1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
HK1173973A1 (en) Antibody therapeutics with local activity in the digestive tract
HRP20181493T1 (hr) Konjugati epsilon-polilizin i njihova primjena
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
ZA201204480B (en) Conjugate with target-finding ligand and use thereof
ZA201207249B (en) Human anti-il-6 antibodies with extended in vivo half-life
EP2478110A4 (en) CLASS I ANTI-CEA ANTIBODIES AND USES THEREOF
IL222812A0 (en) Anti-human trop-2 antibody having antitumor activity in vivo
EP2407508A4 (en) RESIN COMPOSITION AND MULTILAYER STRUCTURE USING THE SAME
HK1195776A1 (zh) -α 抗-α 抗體及其應用
HK1178917A1 (zh) 抗體及其用途
EP2457092A4 (en) CANCER BIOMARKERS AND THEIR USE
IL219435A0 (en) Intraluminal device with improved flexibility and durability
HK1168653A1 (en) A-fucosylation detection in antibodies a-
EP2394001A4 (en) QUASI-ISOTROPIC SANDWICH STRUCTURES
IL199618A0 (en) Novel antibodies and their use in diagnostic methods
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
GB0903151D0 (en) Antibody uses and methods
HK1164193A1 (zh) 抗體及其用途
EP2620449A4 (en) EPIDINATED ANTIBODIES AGAINST B2 AND THE USE THEREOF
EP2510000A4 (en) Anti-inflammatory antibodies and applications thereof
EP2484693A4 (en) ANTI-AMYLOID-A3 ANTIBODIES OF HUMAN SERUM AND USE THEREOF
EP2578682A4 (en) ANTIBODIES AND ITS USE
GB0906115D0 (en) Antibody and uses thereof
GB0911407D0 (en) Antibody and diagnostic use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211021